Literature DB >> 15852389

High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson's disease patients.

Antonio Pisani, Filomena Fezza, Salvatore Galati, Natalia Battista, Simone Napolitano, Alessandro Finazzi-Agrò, Giorgio Bernardi, Livia Brusa, Mariangela Pierantozzi, Paolo Stanzione, Mauro Maccarrone.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15852389     DOI： 10.1002/ana.20462

Source DB:  PubMed          Journal:  Ann Neurol        ISSN： 0364-5134            Impact factor:   10.422


× No keyword cloud information.
  51 in total

Review 1.  Adaptations of striatal endocannabinoid system during stress.

Authors:  Silvia Rossi; Valentina De Chiara; Alessandra Musella; Giorgia Mataluni; Lucia Sacchetti; Giorgio Bernardi; Alessandro Usiello; Diego Centonze
Journal:  Mol Neurobiol       Date:  2009-03-07       Impact factor: 5.590

Review 2.  Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation.

Authors:  Mahmoud M Iravani; Peter Jenner
Journal:  J Neural Transm (Vienna)       Date:  2011-09-01       Impact factor: 3.575

3.  The decrease of dopamine D₂/D₃ receptor densities in the putamen and nucleus caudatus goes parallel with maintained levels of CB₁ cannabinoid receptors in Parkinson's disease: a preliminary autoradiographic study with the selective dopamine D₂/D₃ antagonist [³H]raclopride and the novel CB₁ inverse agonist [¹²⁵I]SD7015.

Authors:  Szabolcs Farkas; Katalin Nagy; Zhisheng Jia; Tibor Harkany; Miklós Palkovits; Sean R Donohou; Victor W Pike; Christer Halldin; Domokos Máthé; László Csiba; Balázs Gulyás
Journal:  Brain Res Bull       Date:  2012-03-07       Impact factor: 4.077

4.  Cannabinoids and value-based decision making: implications for neurodegenerative disorders.

Authors:  Angela M Lee; Erik B Oleson; Leontien Diergaarde; Joseph F Cheer; Tommy Pattij
Journal:  Basal Ganglia       Date:  2012-07-28

5.  Changes in CB(1) and CB(2) receptors in the post-mortem cerebellum of humans affected by spinocerebellar ataxias.

Authors:  Carmen Rodríguez-Cueto; Cristina Benito; Javier Fernández-Ruiz; Julián Romero; Mariluz Hernández-Gálvez; María Gómez-Ruiz
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

Review 6.  The endocannabinoid system as a target for the treatment of neurodegenerative disease.

Authors:  Emma L Scotter; Mary E Abood; Michelle Glass
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

Review 7.  Targeting the endocannabinoid system: a predictive, preventive, and personalized medicine-directed approach to the management of brain pathologies.

Authors:  Vamsi Reddy; Dayton Grogan; Meenakshi Ahluwalia; Évila Lopes Salles; Pankaj Ahluwalia; Hesam Khodadadi; Katelyn Alverson; Andy Nguyen; Srikrishnan P Raju; Pankaj Gaur; Molly Braun; Fernando L Vale; Vincenzo Costigliola; Krishnan Dhandapani; Babak Baban; Kumar Vaibhav
Journal:  EPMA J       Date:  2020-04-15       Impact factor: 6.543

Review 8.  The therapeutic potential of cannabinoids for movement disorders.

Authors:  Benzi Kluger; Piera Triolo; Wallace Jones; Joseph Jankovic
Journal:  Mov Disord       Date:  2015-02-04       Impact factor: 10.338

Review 9.  Endocannabinoids in synaptic plasticity and neuroprotection.

Authors:  Jian-Yi Xu; Chu Chen
Journal:  Neuroscientist       Date:  2014-02-25       Impact factor: 7.519

10.  Loss of cannabinoid CB1 receptor expression in the 6-hydroxydopamine-induced nigrostriatal terminal lesion model of Parkinson's disease in the rat.

Authors:  Sinéad Walsh; Katarzyna Mnich; Ken Mackie; Adrienne M Gorman; David P Finn; Eilís Dowd
Journal:  Brain Res Bull       Date:  2010-01-25       Impact factor: 4.077
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.